VERAXA Biotech (NASDAQ: VRXA), an emerging leader in designing novel cancer therapies, has begun cell line development for its lead BiTAC® T-cell engager program, marking another step in preparing the company’s most advanced oncology candidate for future clinical development. The company announced that it has selected ATUM, a U.S.-based contract research organization specializing in bioengineering and cell line development, to generate stable clonal cell lines using its proprietary Leap-In Transposase® technology.
According to VERAXA, the collaboration is intended to support manufacturing, analytical development, and nonclinical studies required before clinical testing. ATUM will apply its Leap-In Transposase® technology to generate stable clonal cell lines for VERAXA’s lead therapeutic candidate. The collaboration represents an important development milestone as the candidate advances toward IND/CTA-enabling studies.
VERAXA’s BiTAC® platform is designed to improve the selectivity of T-cell engagers, potentially reducing toxicity associated with conventional approaches. The company recently expanded its research facilities in Heidelberg, Germany, increasing laboratory capacity as multiple oncology programs move toward clinical development.
This partnership with ATUM underscores VERAXA’s commitment to advancing its pipeline. For more information on VERAXA Biotech, visit the company’s newsroom at https://ibn.fm/VRXA. Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer.
Forward-looking statements in this article involve risks and uncertainties that may cause actual results to differ materially. These factors are discussed in the Company's filings with the SEC.
